Davide Croce

Davide Croce

Auto-generated profile, based on publicly available information

Davide Croce

Fondazione Milano Cortina 2026, Milan; LIUC University, Castellanza, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2014 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
Giovanni MauriGiovanni Mauri
Giovanni Mauri
EPEmanuele Porazzi
Emanuele Porazzi
LCLuca Cova
Luca Cova
URUmberto Restelli
Umberto Restelli
TTTania Tondolo
Tania Tondolo
Luigi Alessandro SolbiatiLuigi Alessandro Solbiati
Luigi Alessandro Solbiati
Objectives To assess the clinical and the economic impacts of intraprocedural use of contrast-enhanced ultrasound (CEUS) in patients undergoing percutaneous radiofrequency ablation for small (<2.5 cm) hepatocellular carcinomas. Methods One hundred and forty-eight hepatocellular carcinomas in 93 patients were treated by percutaneous radiofrequency ablation and immediate assessment by intraprocedural CEUS. Clinical impact, cost effectiveness, and budget, organisational and equity impacts were evaluated and compared with standard treatment without intraprocedural CEUS using the health technology assessment approach. Results Intraprocedural CEUS detected incomplete ablation in 34/93 (36.5 %) patients, who underwent additional treatment during the same session. At 24-h, complete ablation was found in 88/93 (94.6 %) patients. Thus, a second session of treatment was spared in 29/93 (31.1 %) patients. Cost-effectiveness analysis revealed an advantage for the use of intraprocedural CEUS in comparison with standard treatment (4,639 vs 6,592) with a 21.9 % reduction of the costs to treat the whole sample. Cost per patient for complete treatment was € 4,609 versus € 5,872 respectively. The introduction of intraprocedural CEUS resulted in a low organisational impact, and in a positive impact on equity Conclusions Intraprocedural use of CEUS has a relevant clinical impact, reducing the number of re-treatments and the related costs per patient. Teaching Points • CEUS allows to immediately asses the result of ablation. • Intraprocedural CEUS decreases the number of second ablative sessions. • Intraprocedural CEUS may reduce cost per patient for complete treatment. • Use of intraprocedural CEUS may reduce hospital budget. • Its introduction has low organisational impact, and relevant impact on equity.

1 May 2021 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
FMFrida Milella
Frida Milella
EMEliana Alessandra Minelli
Eliana Alessandra Minelli
FSFernanda Strozzi
Fernanda Strozzi
DCDavide Croce
Davide Croce
Background: Change is an ongoing process in any organizations. Over years, healthcare organizations have been exposed to multiple external stimuli to change (eg, ageing population, increasing incidence of chronic diseases, ongoing Sars-Cov-2 pandemic) that pointed out the need to convert the current healthcare organizational model. Nowadays, the topic is extremely relevant, rendering organizational change an urgency. The work is structured on a double level of analysis. In the beginning, the paper collects the overall literature on the topic of organisational change in order to identify, on the basis of the citation network, the main existing theoretical approaches. Secondly, the analysis attempts to isolate the scientific production related to the healthcare context, by analysing the body of literature outside the identified citation network, divided by clusters of related studies. Methodology: This review adopted a quantitative-based method that employs jointly systematic literature review and bibliographic network analysis. Specifically, the study applied a citation network analysis (CNA) and a co-occurrence keywords analysis. The CNA allowed detecting the most relevant papers published over time, identifying the research streams in literature. Results: The study showed four main findings. Firstly, consistent with past studies, works reviewed pointed out a convergence on the micro-level perspective for change’s analysis. Secondly, an organic viewpoint whereby individual, organization and change’s outcome contribute to any organizational change’s action has been found in its early stage. Thirdly, works reported change combined with innovation’s concept, although the structure of the relationship has not been outlined. Fourth, interestingly, contributions have been limited within the healthcare context. Conclusion: Human dimension is the primary criticality to be managed to impede failure of the re-organizational path. Individuals are not passive recipients of change: individual change acceptance has been found a key input. Few papers discussed healthcare professionals’ behaviour, and those available focused on technology-led changes perspective. In this view, individual acceptance of change within the healthcare context resulted being undeveloped and offers rooms for further analyses.

1 July 2011 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
GRGiuliano Rizzardini
Giuliano Rizzardini
URUmberto Mecon Restelli
Umberto Mecon Restelli
PBPaolo Bonfanti
Paolo Bonfanti
EPEmanuele Mecon Porazzi
Emanuele Mecon Porazzi
RERicci, Elena
Ricci, Elena
DCDavide Meng Croce
Davide Meng Croce
Background: Healthcare expenditures incurred by the Health Service for HIV-infected patients have not been reported in Italy. Objective: To present health care costs for HIV-infected patients in the Lombardy Region, in 2004-2007, to determine the clinical characteristics of HIV infection associated with costs. Methods: Retrospective, observational, budget impact study, based on information collected for the period 2004-2007, including hospitalizations, outpatient services, highly active antiretroviral therapy (HAART) and non-HAART drug utilization. Inclusion criteria includes: confirmed HIV infection, age ≥18 years, resident in Lombardy Region, and followed at the “L. Sacco” Hospital in Milan from 2004 to 2007. Results: The mean total cost per year to provide healthcare to HIV-positive patients was rather stable (€9658.36 in 2004 and €9745.65 in 2007 (+0.90%)); HAART represented more than 60% of the total cost. We found that hepatitis C virus coinfection was related to higher costs (€11,003.45 vs. €8896.06), as well as CD4 cell count <200 cells/mm3 (€12,681.36 vs. €9594.11 and €9450.36 in 200-499 and ≥500 cells/mm3, respectively). The mean total cost of HIV health care was higher in patients who initiated antiretroviral treatment before 1997 than in those who started after 1996. Conclusions: The mean total cost per year to provide health care to HIV-positive patients was stable during the period 2004-2007, with an increase of HAART percentage impact on the total cost. Several clinical characteristics of HIV-infected patients were significantly associated with cost variation.

1 March 2010 in Acta Tropica
Verified
Journal Article
Closed access
DCDavide Croce
Davide Croce
EPEmanuele Porazzi
Emanuele Porazzi
EFEmanuela Foglia
Emanuela Foglia
URUmberto Restelli
Umberto Restelli
MSMuth Sinuon
Muth Sinuon
AMAntonio Montresor
Antonio Montresor

11 August 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
URUmberto Restelli
Umberto Restelli
FSFrancesca Scolari
Francesca Scolari
PBPaolo Bonfanti
Paolo Bonfanti
DCDavide Croce
Davide Croce
GRGiuliano Rizzardini
Giuliano Rizzardini
In the healthcare sector, it is crucial to identify sustainable strategies in order to allow the introduction and use of innovative technologies. Now, and over the next few years, the expiry of patents for different antiretroviral drugs offers an opportunity to increase the efficiency of resources allocation. The aim of the present study was to assess the impact, on the budget of the Italian National Healthcare Service, of generic antiretroviral drugs and of new antiretroviral drugs entering the market from 2015 to 2019. A budget impact model was developed in order to forecast the rate of use of ARTs, based on trends observed within the Lombardy Region (Italy), on clinical experts’ opinion, and the consequent impact on the Italian NHS budget in a five year time horizon. Different scenarios were developed, considering the sole introduction of generic drugs, of new drugs, and their cumulative effects. A multivariate sensitivity analysis was also performed. The cumulative use of generic drugs and new drugs would lead to annual savings of 4.6 million € (-0.6 %) in 2015; 16.9 million € (-2.1 %) in 2016; 19.4 million € (-2.4 %) in 2017; 51.1 million € (-6.1 %) in 2018 and -110.3 million € (-12.8 %) in 2019. The impact of new drugs in percentage terms is +2.0 % in 2015, +3.4 % in 2016, +3.9 % in 2017, +5.7 % in 2018 and +7.7 % in 2019. The impact of generic drugs would lead to savings of 4.9 million € in 2015, 18.6 million € in 2016, 22.8 million € in 2017, 76.5 million € in 2018 and 187.4 million € in 2019. The sensitivity analysis showed annual mean savings for the Italian NHS ranging from 12.6 million €, -1.5 % compared to the base case scenario (decreasing all the rates of transition used in the simulation, and increasing the cost of generic drugs) to 76.0 million €, -9.1 % (increasing all the rates of transition used in the simulation, and decreasing the cost of generic and new drugs). The use of antiretroviral generic drugs may lead to savings that would compensate the expenditure increase due to new, innovative drugs available on the market.

5 June 2017 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
EFEmanuela Foglia
Emanuela Foglia
ELEmanuele Lettieri
Emanuele Lettieri
LFLucrezia Ferrario
Lucrezia Ferrario
EPEmanuele Porazzi
Emanuele Porazzi
EGElisabetta Garagiola
Elisabetta Garagiola
DCDavide Croce
Davide Croce
Objectives: Hospital Based Health Technology Assessment (HBHTA) practices, to inform decision making at the hospital level, emerged as urgent priority for policy makers, hospital managers, and professionals. The present study crystallized the results achieved by the testing of an original framework for HBHTA, developed within Lombardy Region: the IMPlementation of A Quick hospital-based HTA (IMPAQHTA). The study tested: (i) the HBHTA framework efficiency, (ii) feasibility, (iii) the tool utility and completeness, considering dimensions and sub-dimensions.Methods: The IMPAQHTA framework deployed the Regional HTA program, activated in 2008 in Lombardy, at the hospital level. The relevance and feasibility of the framework were tested over a 3-year period through a large-scale empirical experiment, involving seventy-four healthcare professionals organized in different HBHTA teams for assessing thirty-two different technologies within twenty-two different hospitals. Semi-structured interviews and self-reported questionnaires were used to collect data regarding the relevance and feasibility of the IMPAQHTA framework.Results: The proposed HBHTA framework proved to be suitable for application at the hospital level, in the Italian context, permitting a quick assessment (11 working days) and providing hospital decision makers with relevant and quantitative information. Performances in terms of feasibility, utility, completeness, and easiness proved to be satisfactory.Conclusions: The IMPAQHTA was considered to be a complete and feasible HBHTA framework, as well as being replicable to different technologies within any hospital settings, thus demonstrating the capability of a hospital to develop a complete HTA, if supported by adequate and well defined tools and quantitative metrics.